Wealth Enhancement Trust Services
RNA icon

Wealth Enhancement Trust Services’s Atrium Therapeutics RNA Stock Holding History

Wealth Enhancement Trust Services’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-40
Closed -$538 – 1577
2026
Q2 		$538 Buy
+40
New +$522 ﹤0.01% 1232

Other funds holding RNA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
Arbiter Partners Capital Management
Arbiter Partners Capital Management New York $235M AUM 94.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
BlueCrest Capital Management
BlueCrest Capital Management St Helier, Jersey $2.76B AUM 15.17% 1-Year Est. Return
Quantinno Capital Management
Quantinno Capital Management New York $106B AUM 29.93% 1-Year Est. Return
Yakira Capital Management
Yakira Capital Management Westport, Connecticut $397M AUM 11.81% 1-Year Est. Return
AIC
AWM Investment Company New York $1.04B AUM 103.31% 1-Year Est. Return

Wealth Enhancement Trust Services's RNA Position: Q3 2026 in Review

Wealth Enhancement Trust Services sold out of Atrium Therapeutics (RNA) in Q3 2026, closing a stake of 40 shares — an estimated $538 sold.

Wealth Enhancement Trust Services first reported a position in RNA in Q2 2026 and held it in 1 quarter. The position peaked at $538 in Q2 2026. 96 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Wealth Enhancement Trust Services reported no remaining Atrium Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Trust Services sold 40 Atrium Therapeutics shares in Q3 2026, an estimated $538.
  • Wealth Enhancement Trust Services first reported a position in Atrium Therapeutics in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Trust Services's Atrium Therapeutics position peaked at $538 in Q2 2026.
  • 96 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q3 2026, filed 7 Oct 2026.